Iradimed Co (IRMD)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $1.09B
Last updated: Nov 17, 2026 at 11:05 AM ET
Iradimed Co (IRMD) Financials: Revenue, Profit and Cash Flow
Iradimed reported revenue of $83.81M for the fiscal year ended Dec 31, 2025, up 14.4% from the year before. That year, net income was $22.48M with a net margin of 26.8%, operating cash flow was $24.95M and free cash flow was $16.53M. The quarter ended Sep 30, 2026 had revenue of $24.20M and net income of $6.51M.
Revenue and Margins
The operating margin was 31.2% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $32.50M, a compound annual rate of 11.1%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $83.81M | +14.4% | 76.7% | 31.2% | 26.8% |
| Dec 2024 | $73.24M | +11.7% | 76.9% | 30.0% | 26.3% |
| Dec 2023 | $65.56M | +23.0% | 76.5% | 30.6% | 26.2% |
| Dec 2022 | $53.30M | +27.5% | 77.4% | 29.3% | 24.1% |
| Dec 2021 | $41.81M | +31.8% | 76.6% | 23.5% | 22.3% |
| Dec 2020 | $31.72M | -17.7% | 74.3% | -2.4% | 4.3% |
| Dec 2019 | $38.52M | +26.5% | 77.1% | 22.5% | 25.0% |
| Dec 2018 | $30.44M | +31.9% | 76.3% | 19.7% | 20.7% |
| Dec 2017 | $23.08M | -29.0% | 75.9% | 5.6% | 2.2% |
| Dec 2016 | $32.50M | N/A | 81.1% | 33.6% | 22.2% |
Income Statement
In the fiscal year ended Dec 2025, net income rose 16.9% from the year before. In the quarter ended Sep 2026, net income rose 16.7% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $83.81M | $73.24M | $65.56M | $53.30M | $41.81M | $31.72M | $38.52M | $30.44M | $23.08M | $32.50M |
| Cost of revenue | $19.49M | $16.89M | $15.40M | $12.02M | $9.76M | $8.14M | $8.82M | $7.21M | $5.57M | $6.15M |
| Gross profit | $64.32M | $56.35M | $50.16M | $41.28M | $32.05M | $23.57M | $29.70M | $23.23M | $17.51M | $26.34M |
| Research and development | $2.98M | $2.83M | $2.86M | $2.28M | $1.91M | $1.90M | $1.43M | $1.52M | $1.72M | $1.35M |
| Operating income | $26.15M | $21.96M | $20.04M | $15.63M | $9.82M | -$756.09K | $8.65M | $6.00M | $1.29M | $10.92M |
| Net income | $22.48M | $19.23M | $17.19M | $12.83M | $9.33M | $1.37M | $9.63M | $6.30M | $499.76K | $7.21M |
| EBITDA | $29.53M | $25.09M | $22.50M | $16.85M | $11.24M | $721.95K | $10.29M | $7.30M | $2.71M | $11.91M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $24.20M | $20.47M | $21.98M | $22.69M | $21.20M | $20.41M | $19.51M | $19.39M | $18.33M | $17.93M | $17.60M | $17.45M |
| Gross profit | $18.46M | $15.16M | $16.81M | $17.03M | $16.49M | $15.96M | $14.84M | $14.76M | $14.19M | $14.01M | $13.39M | $13.41M |
| Operating income | $8.14M | $6.39M | $7.24M | $7.09M | $6.83M | $6.79M | $5.43M | $5.80M | $5.79M | $5.63M | $4.75M | $5.16M |
| Net income | $6.51M | $5.22M | $5.82M | $6.44M | $5.58M | $5.77M | $4.69M | $5.15M | $5.05M | $4.90M | $4.14M | $4.54M |
Balance Sheet
As of Dec 2025, cash and equivalents of $51.16M were 47.0% of total assets of $108.78M, against total liabilities of $14.16M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $108.78M | $98.33M | $92.16M | $85.51M | $82.88M | $71.07M | $66.73M | $48.44M | $39.01M | $37.19M |
| Current assets | $81.20M | $75.24M | $76.00M | $77.49M | $76.24M | $63.74M | $58.96M | $44.54M | $35.11M | $33.86M |
| Cash and equivalents | $51.16M | $52.23M | $49.76M | $57.96M | $62.00M | $50.07M | $43.48M | $28.03M | $18.21M | $17.71M |
| Total liabilities | $14.16M | $11.51M | $20.74M | $11.84M | $10.71M | $9.68M | $11.20M | $6.50M | $6.08M | $5.31M |
| Short-term debt | N/A | $153.26K | $427.96K | $293.47K | $276.57K | $255.70K | $240.84K | $133.00K | $1.70M | $1.39M |
| Shareholder equity | $94.62M | $86.82M | $71.42M | $73.67M | $72.17M | $61.38M | $55.52M | $41.95M | $32.93M | $31.89M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $121.07M | $114.97M | $114.39M | $108.78M | $114.72M | $106.45M | $101.73M | $98.33M | $94.25M | $89.95M | $88.01M | $92.16M |
| Total liabilities | $14.62M | $13.23M | $15.88M | $14.16M | $16.37M | $12.15M | $11.68M | $11.51M | $10.81M | $10.28M | $11.89M | $20.74M |
| Cash and equivalents | $63.29M | $59.08M | $56.37M | $51.16M | $56.53M | $53.00M | $50.33M | $52.23M | $51.72M | $48.54M | $45.13M | $49.76M |
| Shareholder equity | $106.45M | $101.75M | $98.51M | $94.62M | $98.35M | $94.30M | $90.05M | $86.82M | $83.43M | $79.67M | $76.12M | $71.42M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 66.3% of operating cash flow. Dividends came to 91.0% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $24.95M | $25.62M | $13.47M | $10.04M | $11.26M | $5.82M | $10.23M | $7.38M | $3.42M | $9.41M |
| Capital expenditures | $8.42M | $8.82M | $8.01M | $1.87M | $741.76K | $636.75K | $485.81K | $264.67K | $824.76K | $1.52M |
| Free cash flow | $16.53M | $16.81M | $5.46M | $8.17M | $10.52M | $5.18M | $9.75M | $7.11M | $2.59M | $7.88M |
| Dividends paid | $15.04M | $13.68M | $13.22M | $12.56M | $0 | $12.56M | $12.56M | N/A | $0 | $0 |
| Share repurchases | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $1.82M | $9.97M |
| Investing cash flow | -$8.42M | -$8.82M | -$8.01M | -$1.37M | $648.24K | $246.97K | $3.20M | $1.52M | -$1.02M | -$1.94M |
| Financing cash flow | -$17.60M | -$14.34M | -$13.66M | -$12.71M | $24.43K | $522.48K | $2.02M | $929.87K | -$1.90M | -$9.12M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $7.00M | $5.94M | $8.29M | $5.92M | $6.99M | $7.75M | $4.29M | $5.99M | $9.12M | $6.64M | $3.88M | $3.91M |
| Capital expenditures | $130.00K | $185.00K | $403.00K | $416.41K | $1.14M | $2.64M | $3.70M | $3.06M | $4.01M | $1.27M | $478.80K | $632.82K |
| Free cash flow | $6.87M | $5.75M | $7.89M | $5.51M | $5.85M | $5.11M | $595.00K | $2.93M | $5.10M | $5.37M | $3.40M | $3.28M |
Frequently Asked Questions About IRMD
What is Iradimed's annual revenue?
Iradimed reported revenue of $83.81M for the fiscal year ended Dec 31, 2025.
How fast is Iradimed's revenue growing?
Revenue was up 14.4% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 16.3%.
Is Iradimed profitable?
Yes. Iradimed reported net income of $22.48M for the fiscal year ended Dec 31, 2025, with a net margin of 26.8%.
How much free cash flow does IRMD generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $24.95M minus capital expenditures of $8.42M produced free cash flow of $16.53M.
How much debt does Iradimed have?
The balance sheet dated Dec 31, 2025 reported cash and equivalents of $51.16M.
IRMD pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts